Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review

Shoji Yokobori, Khadil Hosein, Stephen Burks, Ishna Sharma, Shyam Gajavelli, Ross Bullock

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Rapid triage and decision-making in the treatment of traumatic brain injury (TBI) present challenging dilemma in "resource poor" environments such as the battlefield and developing areas of the world. There is an urgent need for additional tools to guide treatment of TBI. The aim of this review is to establish the possible use of diagnostic TBI biomarkers in (1) identifying diffuse and focal brain injury and (2) assess their potential for determining outcome, intracranial pressure (ICP), and responses to therapy. At present, there is insufficient literature to support a role for diagnostic biomarkers in distinguishing focal and diffuse injury or for accurate determination of raised ICP. Presently, neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-tau, neuron-specific enolase (NSE), S100β, GFAP, and spectrin breakdown products (SBDPs) appear to be candidates for ICP reflective biomarkers. With the combinations of different pathophysiology related to each biomarker, a multibiomarker analysis seems to be effective and would likely increase diagnostic accuracy. There is limited research focusing on the differential diagnostic properties of biomarkers in TBI. This fact warrants the need for greater efforts to innovate sensitive and reliable biomarkers. We advocate awareness and inclusion of the differentiation of injury type and ICP elevation in further studies with brain injury biomarkers.

Original languageEnglish
Pages (from-to)556-565
Number of pages10
JournalCNS Neuroscience and Therapeutics
Volume19
Issue number8
DOIs
StatePublished - Aug 1 2013

Fingerprint

Differential Diagnosis
Biomarkers
Intracranial Pressure
Glial Fibrillary Acidic Protein
Brain Injuries
Wounds and Injuries
Spectrin
Intracranial Hypertension
Intermediate Filaments
Traumatic Brain Injury
Phosphopyruvate Hydratase
Triage
Hydrolases
Ubiquitin
Decision Making
Research

Keywords

  • Biomarkers
  • Differential diagnosis
  • Intracranial hypertension
  • Pathophysiology
  • Traumatic brain injury

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology

Cite this

Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review. / Yokobori, Shoji; Hosein, Khadil; Burks, Stephen; Sharma, Ishna; Gajavelli, Shyam; Bullock, Ross.

In: CNS Neuroscience and Therapeutics, Vol. 19, No. 8, 01.08.2013, p. 556-565.

Research output: Contribution to journalArticle

Yokobori, S, Hosein, K, Burks, S, Sharma, I, Gajavelli, S & Bullock, R 2013, 'Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review', CNS Neuroscience and Therapeutics, vol. 19, no. 8, pp. 556-565. https://doi.org/10.1111/cns.12127
Yokobori, Shoji ; Hosein, Khadil ; Burks, Stephen ; Sharma, Ishna ; Gajavelli, Shyam ; Bullock, Ross. / Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review. In: CNS Neuroscience and Therapeutics. 2013 ; Vol. 19, No. 8. pp. 556-565.
@article{4ffe3084bf544329a759ee3cd78a16b5,
title = "Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review",
abstract = "Rapid triage and decision-making in the treatment of traumatic brain injury (TBI) present challenging dilemma in {"}resource poor{"} environments such as the battlefield and developing areas of the world. There is an urgent need for additional tools to guide treatment of TBI. The aim of this review is to establish the possible use of diagnostic TBI biomarkers in (1) identifying diffuse and focal brain injury and (2) assess their potential for determining outcome, intracranial pressure (ICP), and responses to therapy. At present, there is insufficient literature to support a role for diagnostic biomarkers in distinguishing focal and diffuse injury or for accurate determination of raised ICP. Presently, neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-tau, neuron-specific enolase (NSE), S100β, GFAP, and spectrin breakdown products (SBDPs) appear to be candidates for ICP reflective biomarkers. With the combinations of different pathophysiology related to each biomarker, a multibiomarker analysis seems to be effective and would likely increase diagnostic accuracy. There is limited research focusing on the differential diagnostic properties of biomarkers in TBI. This fact warrants the need for greater efforts to innovate sensitive and reliable biomarkers. We advocate awareness and inclusion of the differentiation of injury type and ICP elevation in further studies with brain injury biomarkers.",
keywords = "Biomarkers, Differential diagnosis, Intracranial hypertension, Pathophysiology, Traumatic brain injury",
author = "Shoji Yokobori and Khadil Hosein and Stephen Burks and Ishna Sharma and Shyam Gajavelli and Ross Bullock",
year = "2013",
month = "8",
day = "1",
doi = "10.1111/cns.12127",
language = "English",
volume = "19",
pages = "556--565",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Biomarkers for the clinical differential diagnosis in traumatic brain injury-A systematic review

AU - Yokobori, Shoji

AU - Hosein, Khadil

AU - Burks, Stephen

AU - Sharma, Ishna

AU - Gajavelli, Shyam

AU - Bullock, Ross

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Rapid triage and decision-making in the treatment of traumatic brain injury (TBI) present challenging dilemma in "resource poor" environments such as the battlefield and developing areas of the world. There is an urgent need for additional tools to guide treatment of TBI. The aim of this review is to establish the possible use of diagnostic TBI biomarkers in (1) identifying diffuse and focal brain injury and (2) assess their potential for determining outcome, intracranial pressure (ICP), and responses to therapy. At present, there is insufficient literature to support a role for diagnostic biomarkers in distinguishing focal and diffuse injury or for accurate determination of raised ICP. Presently, neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-tau, neuron-specific enolase (NSE), S100β, GFAP, and spectrin breakdown products (SBDPs) appear to be candidates for ICP reflective biomarkers. With the combinations of different pathophysiology related to each biomarker, a multibiomarker analysis seems to be effective and would likely increase diagnostic accuracy. There is limited research focusing on the differential diagnostic properties of biomarkers in TBI. This fact warrants the need for greater efforts to innovate sensitive and reliable biomarkers. We advocate awareness and inclusion of the differentiation of injury type and ICP elevation in further studies with brain injury biomarkers.

AB - Rapid triage and decision-making in the treatment of traumatic brain injury (TBI) present challenging dilemma in "resource poor" environments such as the battlefield and developing areas of the world. There is an urgent need for additional tools to guide treatment of TBI. The aim of this review is to establish the possible use of diagnostic TBI biomarkers in (1) identifying diffuse and focal brain injury and (2) assess their potential for determining outcome, intracranial pressure (ICP), and responses to therapy. At present, there is insufficient literature to support a role for diagnostic biomarkers in distinguishing focal and diffuse injury or for accurate determination of raised ICP. Presently, neurofilament (NF), S100β, glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1) seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-tau, neuron-specific enolase (NSE), S100β, GFAP, and spectrin breakdown products (SBDPs) appear to be candidates for ICP reflective biomarkers. With the combinations of different pathophysiology related to each biomarker, a multibiomarker analysis seems to be effective and would likely increase diagnostic accuracy. There is limited research focusing on the differential diagnostic properties of biomarkers in TBI. This fact warrants the need for greater efforts to innovate sensitive and reliable biomarkers. We advocate awareness and inclusion of the differentiation of injury type and ICP elevation in further studies with brain injury biomarkers.

KW - Biomarkers

KW - Differential diagnosis

KW - Intracranial hypertension

KW - Pathophysiology

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84880703738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880703738&partnerID=8YFLogxK

U2 - 10.1111/cns.12127

DO - 10.1111/cns.12127

M3 - Article

C2 - 23710877

AN - SCOPUS:84880703738

VL - 19

SP - 556

EP - 565

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 8

ER -